COR: Specialty-driven growth and MSO integration position the business for sustained momentum through 2027
Strong specialty pharma growth is expected to continue through 2027, driven by focused investments in oncology and retina, integration of MSO platforms, and robust international performance. Regulatory and customer dynamics are being managed proactively, with capital allocation priorities unchanged…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.